Dr. Theeraya Krisdaphong, Chief Executive Officer of Specialty Natural Products Public Company Limited (SET: SNPS), shared an overview of the company’s operations through the “Opportunity Day” event organized by The Stock Exchange of Thailand (SET) on June 4, 2025.
SNPS reported 1Q25 net profit of THB 19.77 million, a robust 63.15% increase from THB 12.12 million in the same period last year. This growth was underpinned by a 19.84% year-on-year increase in total revenue to THB 120.83 million.
The revenue growth was largely attributed to a remarkable 73.66% increase in sales of Active Phyto‑Innovention (API), as well as the company’s product innovation strategies designed to serve both new and existing customers.
Looking ahead, SNPS anticipates significant revenue upswings in Q2 and Q3 each year. This is due to the company’s business position at the upstream segment—covering both material extraction and Original Equipment Manufacturer (OEM) product manufacturing. SNPS’s customers typically plan new product launches during these quarters, resulting in a steady influx of orders.
For the 2025 outlook, SNPS has set four core operational strategies: (1) emphasize building a portfolio of innovative products with distinct market offerings, (2) expand market presence, (3) strengthen supply chain, and (4) advance IT, branded ingredient, and high-value API development—all focused on elevating the company’s growth trajectory.
SNPS currently segments product portfolios into three main groups: cosmetics, food, and pharmaceuticals. The company’s domestic market focus is on the pharma segment, where demand is on the rise, especially for conditions treatable with traditional herbal products (National Remedies), which are also essential for daily life.
For international markets, considering the regulatory complexities for pharmaceuticals in each country, SNPS is initially targeting cosmetics and nutraceutical segments.
The company has already established partnerships in eight countries—India, France, Indonesia, Malaysia, Singapore, Australia, and Austria—for product distribution. SNPS is also active in overseas exhibitions and international business events in countries such as Indonesia, Spain, India, Thailand, South Korea, China, and the United Arab Emirates.
In 2025, SNPS plans to introduce a continuous stream of new products, prioritizing Active Phyto Ingredients (API) with at least 2-3 “Big Series” products, which are high-value APIs.
Additionally, SNPS is committed to developing innovative formulas across cosmeceuticals, nutraceuticals, and pharmaceuticals. The company is capable of developing up to 10 new formulas each month.
Innovation in product development is the group’s signature. SNPS selects products with strong demand and in tune with today’s nature-driven trends—products that genuinely work, without causing negative long-term impact, said Dr. Theeraya.
On the matter of rising U.S. tariffs, the company is closely monitoring the situation. Dr. Theeraya views this as an opportunity rather than a risk, as manufacturers, especially from Europe, show increasing interest in relocating production bases to Thailand.
For the first half of 2025, SNPS’s performance aligns with forecasts. After completing the IPO listing, the group has two major projects in focus for 2025–2026: developing various herbal medicines, such as Colosure—which has been fully researched—and four additional projects, with nearly THB 100 million earmarked for investment, including machinery upgrades.
Following these developments, SNPS is targeting an average annual revenue growth rate of 24%, with organic growth expected to hit an impressive 15–30% in 2025. The company also aims for revenue to reach THB 600 million in 2025 and THB 700 million in 2026.
